Intravenous (IV) Pantoprazole in Erosive Esophagitis | RxWiki

Intravenous (IV) Pantoprazole in Erosive Esophagitis

Overview[ - collapse ][ - ]

Purpose	The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
Condition	Esophagitis
Intervention	Drug: pantoprazole
Phase	Phase 4
Sponsor	Emory University
Responsible Party	Emory University
ClinicalTrials.gov Identifier	NCT00133770
First Received	August 22, 2005
Last Updated	July 29, 2013
Last verified	July 2013

Tracking Information[ + expand ][ + ]

First Received Date	August 22, 2005
Last Updated Date	July 29, 2013
Start Date	July 2004
Estimated Primary Completion Date	March 2007
Current Primary Outcome Measures	the percentage of patients healed from severe esophagitis with IV pantoprazole at 7 days [Time Frame: 7 days] [Designated as safety issue: Yes]the percentage of patients healed from severe esophagitis with IV pantoprazole at 7 days
Current Secondary Outcome Measures	Not Provided

Descriptive Information[ + expand ][ + ]

Brief Title	Intravenous (IV) Pantoprazole in Erosive Esophagitis
Official Title	A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis
Brief Summary	The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
Detailed Description	Gastroesophageal reflux disease (GERD) is a very common disease that affects 20-50% of adults in Western Countries. The disease can be divided into three clinical categories: nonerosive reflux disease (NERD), erosive reflux disease (ERD), and Barrett's esophagus. Intravenous (IV) infusion produces a faster and steadier acid suppression than an oral regimen. Furthermore, some patients with severe erosive esophagitis cannot take pills by mouth and will benefit from an IV formulation. Recently, we observed healing of severe erosive esophagitis with continuous IV pantoprazole in several patients in 3 days. The safety of IV pantoprazole has been demonstrated in patients with GERD, with Zollinger-Ellison syndrome, or bleeding ulcer. This study is to define the safety and efficacy of continuous IV pantoprazole in the treatment of severe erosive esophagitis. Comparison: The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis.
Study Type	Interventional
Study Phase	Phase 4
Study Design	Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Condition	Esophagitis
Intervention	Drug: pantoprazole The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis Other Names: Protonix
Study Arm (s)	Experimental: IV pantoprazole The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis

Recruitment Information[ + expand ][ + ]

Recruitment Status	Completed
Estimated Enrollment	20
Estimated Completion Date	March 2007
Estimated Primary Completion Date	July 2006
Eligibility Criteria	Inclusion Criteria: - Patients must be men or non-pregnant women (a documented negative pregnancy test at enrollment for females of child bearing age) at least 18 years of age - Patients who present with a severe erosive esophagitis - confirmed by endoscopy (a baseline endoscopy within 24 hours of study enrollment) to be grade five or six, with or without stricture and/or ulcer - Patients or their legally authorized representatives must be capable of understanding or giving signed and dated informed consent before the study - Patients with a high probability for compliance and completion of the study Exclusion Criteria: - Patients with less than grade five esophagitis - Patients with esophagitis other than reflux esophagitis, such as infectious esophagitis and esophageal cancer - Patients who present with gastrointestinal bleeding, hematocrit decrease greater than 6 units or require more than 2 units transfusion at the presentation or during the time of the study - Patients with severe comorbidities, such as liver diseases with asparate transaminase (AST) or alanine transaminase (ALT) greater than 3 times upper limit normal (ULN); alkaline phosphatase greater than 5 times the ULN; total bilirubin greater than 3.0 mg/dl; kidney diseases with serum creatinine greater than 2.0 mg/dl in men or 1.6 mg/dl in women; heart diseases; lung diseases; sepsis; and airway intubation. - Patients with history of glaucoma in either eye; history of any intraocular eye surgery within preceding 3 months; history of, or presence of, signs of optic nerve swelling; history of acute change in vision; or vision loss in either eye. - Patients with any malignancy (except skin cancer) which required therapy within the last 6 months - Patients with history of allergy to any proton-pump inhibitor (PPI) including pantoprazole - Patients with known human immunodeficiency virus infection - Patients with organ transplantation - Patients without the ability to comply with the study protocol and complete the study in the judgment of the investigator - Patients with prior administration of any PPI (within 72 hours) or histamine-2 receptor antagonist (within previous 24 hours) of study enrollment
Gender	Both
Ages	18 Years
Accepts Healthy Volunteers	No
Contacts	Not Provided
Location Countries	United States

Administrative Information[ + expand ][ + ]

NCT Number	NCT00133770
Other Study ID Numbers	259-2004
Has Data Monitoring Committee	No
Information Provided By	Emory University
Study Sponsor	Emory University
Collaborators	Wyeth is now a wholly owned subsidiary of Pfizer
Investigators	Principal Investigator: Qiang Cai, MD, PhD Emory University
Verification Date	July 2013

Locations[ + expand ][ + ]